Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
Two children with bone marrow necrosis at diagnosis or at relapse of acute lymphoblastic leukemia (ALL) had thrombotic complications 15 and 17 days after starting remission induction therapy including prednisone, vincristine, and L-asparaginase. The close temporal relationship of these two relatively rare events suggests that bone marrow necrosis is a predisposing factor to the development of thrombosis.
Eguiguren
J M
JM
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Pui
C H
CH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D001798:Blood Proteins / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000008:administration & dosage; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D002542:Intracranial Embolism and Thrombosis / Q000209:etiology*; D007958:Leukocyte Count; D008297:Male; D009336:Necrosis / Q000209:etiology*; D010976:Platelet Count; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D001798:Blood Proteins; D006454:Hemoglobins; D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin